Mural Oncology plc MURA · Stock Open Mural Oncology plc in new tab
Mural Oncology plc Analysis (MURA)
Is Mural Oncology plc a good investment? Mural Oncology plc (MURA) is currently trading at 2.04 USD.
Earnings Schedule: Mural Oncology plc is expected to release its next earnings report on March 10, 2026. The market consensus estimate for Forward EPS is -5.07.
Investor FAQ
Does Mural Oncology plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Mural Oncology plc?
Mural Oncology plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be March 10, 2026. The company currently has a trailing EPS of -6.93.
Company Profile
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.
Community Discussion